Suchergebnisse

CorMedix’s CRMD lead product, DefenCath (taurolidine plus heparin), is the company’s primary source of revenues. DefenCath was approved in 2023 as the first and only antimicrobial catheter lock

Morgan Stanley’s MS fourth-quarter 2025 earnings of $2.68 per share easily outpaced the Zacks Consensus Estimate of $2.41. Also, the bottom line jumped 21% from the prior-year quarter.Unlike its

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced that its HiFi whole-genome sequencing technology has been adopted as a first-line approach in a major

AXIL Brands AXIL shares have jumped 29.7% since reporting second-quarter fiscal 2026 results on Jan. 8. The upside was driven by solid top-line growth, expanding operating income and improved

WaFd, Inc.’s WAFD first-quarter fiscal 2026 (ended Dec. 31) earnings of 79 cents per share beat the Zacks Consensus Estimate of 76 cents. The bottom line also jumped 46% year over year. Results

BP plc BP, a leading integrated energy giant, announced its updated fourth-quarter 2025 and full-year guidance. BP has increased its underlying effective tax rate for 2025 to 42% from 40% in its

Coherent Corp.’s COHR AI-play is helping it pay out dividends, as evidenced by notable growth in its top line over the past quarters. Looking at its fiscal 2025 performance, we are impressed by how

State Street’s STT fourth-quarter 2025 adjusted earnings of $2.97 per share surpassed the Zacks Consensus Estimate of $2.82. The bottom line increased 14.2% from the prior-year quarter.Results have

M&T Bank Corporation MTB reported fourth-quarter 2025 net operating earnings per share of $4.72, which beat the Zacks Consensus Estimate of $4.44. The bottom line compared favorably with earnings of